Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015

Date: August 19, 2015
Pages: 1249
Price:
US$ 2,500.00 US$ 2,000.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AFC23A1DAACEN
Leaflet:

Download PDF Leaflet

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015’, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview
Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Recent Pipeline Updates
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1185
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1197
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1203
Appendix 1213

LIST OF TABLES

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2015
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Development by Companies, H2 2015 (Contd..20)
Products under Development by Companies, H2 2015 (Contd..21)
Products under Development by Companies, H2 2015 (Contd..22)
Products under Development by Companies, H2 2015 (Contd..23)
Products under Development by Companies, H2 2015 (Contd..24)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories, LLC, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics B.V., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Akinion Pharmaceuticals AB, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corporation, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascenta Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BIND Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioInvent International AB, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx, Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boston Biomedical, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corporation, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corporation, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis S.A., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celyad, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Clevexel Pharma SAS, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CureTech Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime B.V., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Debiopharm International S.A., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DiNonA Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Egenix, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem, S.L., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Exelixis, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fortress Biotech, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fujifilm Corporation, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genoscience Pharma, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corporation, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gilead Sciences, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Golden Biotechnology Corp., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hybrigenics S.A., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica Biotherapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ignyta, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune System Key Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunoGen, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corporation, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corporation, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Juno Therapeutics Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corporation, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kinex Pharmaceuticals, LLC, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Komipharm International Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lead Discovery Center GmbH, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MaxCyte, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MedImmune, LLC, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co., Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus B.V., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mirna Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MolMed S.p.A., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NantKwest, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Neumedicines Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Limited, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OXiGENE, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharma Mar, S.A., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmacyclics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen S.p.A., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rich Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sellas Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita SA, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Senhwa Biosciences, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sentinel Oncology Limited, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SpectraMab GmbH, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Syros Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tautatis Incorporated, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Theravectys SA, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Trillium Therapeutics Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Verastem, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Vichem Chemie Research Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Viralytics Ltd., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xencor, Inc., H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Xenetic Biosciences plc, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics - Recent Pipeline Updates, H2 2015
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, H2 2015 1220
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..1), H2 2015 1221
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..2), H2 2015 1222
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..3), H2 2015 1223
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..4), H2 2015 1224
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..5), H2 2015 1225
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..6), H2 2015 1226
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..7), H2 2015 1227
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..8), H2 2015 1228
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..9), H2 2015 1229
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..10), H2 2015 1230
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects (Contd..11), H2 2015 1231
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, H2 2015 1232
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..1), H2 2015 1233
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..2), H2 2015 1234
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..3), H2 2015 1235
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..4), H2 2015 1236
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products (Contd..5), H2 2015

LIST OF FIGURES

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2015
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Skip to top


Ask Your Question

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: